 Anticholesteremic Agents
"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 3 | 4 | 7 | | 2006 | 2 | 0 | 2 | | 2007 | 1 | 5 | 6 | | 2008 | 0 | 1 | 1 | | 2009 | 5 | 1 | 6 | | 2011 | 2 | 1 | 3 | | 2012 | 7 | 2 | 9 | | 2013 | 2 | 0 | 2 | | 2014 | 3 | 0 | 3 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 4 | 1 | 5 | | 2018 | 4 | 6 | 10 | | 2019 | 5 | 1 | 6 | | 2020 | 8 | 1 | 9 | | 2021 | 4 | 1 | 5 | | 2022 | 5 | 0 | 5 | | 2023 | 5 | 0 | 5 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Ortega-Paz L, Bonaca M, Angiolillo DJ. Optimizing LDL-cholesterol management in ACS patients: Breaking inertia and implementing intensified therapies. Int J Cardiol. 2024 Apr 01; 400:131803.
-
Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Landmesser U, Koenig W, Leiter LA, Raal FJ, Ray KK, Wright RS, Han J, Conde LG, Schwartz GG. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
-
Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 2024 01 16; 149(3):192-203.
-
Canonico ME, Hess CN, Cannon CP. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? Curr Atheroscler Rep. 2023 07; 25(7):381-389.
-
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
-
Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
-
McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, Nash B, Gillard KK, Ray KK. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs. 2023 Jan; 23(1):67-76.
-
Abushamat LA, Ballantyne CM. Lowering LDL cholesterol in clinical practice: time for change? Lancet. 2022 07 30; 400(10349):341-343.
-
Hagstr?m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 08 30; 146(9):657-672.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|